Introduction
Granulomatosis with polyangiitis (GPA) (formerly Wegener´s granulomatosis) and microscopic polyangiitis (MPA) are vasculitic diseases characterized by necrotizing vessel wall inflammation and anti-neutrophil cytoplasma antibodies (ANCA) directed to proteinase-3 (PR3) or myeloperoxidase (MPO). Similar organ manifestations can be found in the kidneys, peripheral nerves, skin and joints in both diseases, whereas granulomatous lesions in lungs and nose are restricted to GPA. Although considered uncommon, many case reports have been published concerning gastrointestinal (GI) involvement in MPA (1, 2) and GPA (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . In older literature the occurrence of GI involvement was reported to be 5-11% in GPA (7, 15 ) and 6-56% in MPA (16) . In a more recent paper, GI disease was found in 7% of 673 subjects with MPA or GPA included in EUVAS or French clinical trials (17) . Previously,
MPA was not delineated from polyarteritis nodosa (PAN) in the American College of
Rheumatology (ACR) criteria from 1990, so there is confusion concerning the classification of these diseases when older and more recent reports are compared. In 1999 it was reported that 14-40% of PAN patients had GI disease (16) . High incidence rates of GI involvement have also been reported for adult IgA vasculitis (formerly known as Henoch Schönlein purpura) (48%) (18) and eosinophilic granulomatosis with polyangiitis (8-62%) (16) , which is another pauci-immune small vessel vasculitis sometimes associated with ANCA.
The diagnostic procedure of GI symptoms in GPA or MPA patients has been included in previous case reports and to some extent also in larger case series (19) . The aim of the present study was to evaluate GI disease in a large consecutive series of MPA and GPA patients seen at a tertiary referral center in Sweden.
We wanted to study the diagnostic procedure more in detail, and also prognosis as reflected by patient survival. In previous studies patient survival has been worse in GPA and MPA patients with GI disease (17, 20) . We also wanted to focus on the surgical procedures to see if these patients should be handled differently from other patients with GI perforation or bleeding.
Methods
Patient retrieval. The county of Östergötland is located in south-east Sweden and has a population of 440000. In 1997 we initiated a prospective register to include all newly diagnosed patients with GPA and MPA living in this area. All of these patients are treated at the departments of Rheumatology or Nephrology at Linköping University Hospital. Tertiary referred patients from other regions, as well as patients diagnosed before 1997, were also included in this regional vasculitis registry. Data from patients with gastrointestinal disease were retrospectively extracted from patient charts. Birmingham vasculitis activity score (BVAS v.3) was used for definition of organ manifestations and clinical disease activity (21) . BVAS scores were recorded at the time of visit in patients diagnosed after 1997, and estimated by retrospective chart review in patients diagnosed before 1997. Date of diagnosis was defined by start of induction therapy.
Classification. Vasculitis was diagnosed as described by Watts el al, and classified as GPA and MPA using the European Medicines Agency (EMA) algorithm (22) .
Patients were categorized into serotypes based on PR3-ANCA or MPO-ANCA judged by enzyme linked immunosorbent assays (conventional ELISA, capture ELISA, or high-sensitivity ELISA). Before 1997 only results regarding immunofluorescent ANCA-staining patterns ('cytoplasmic' and 'peripheral' staining-patterns, i.e. "C-ANCA" and "P-ANCA", based on ethanol-fixed polymorphonuclear neutrophilic granulocytes) were available for some GPA and MPA patients, but only from one suffering from GI disease. Patients with C-ANCA were grouped together with anti-PR3-positive and P-ANCA with anti-MPO-positive patients.
GI involvement was defined as proposed by Pagnoux: 1) GI symptoms, such as diffuse abdominal pain with acute onset or GI bleeding, that were present at the time of GPA or MPA diagnosis (or within the next 3 months) and responded to specific therapy for vasculitis; 2) GI symptoms that occurred during a relapse, diagnosed on the basis of extraintestinal features of GPA or MPA and/or responded to specific therapy for vasculitis; and/or 3) GI tract vasculitis that was histologically proven on biopsy or at autopsy (19) . In order to qualify for inclusion in the present study, symptoms should not have been caused by GI infection (i.e. Candida albicans, Cytomegalo-virus, Clostridium difficile) or nausea caused by drugs such as cyclophosphamide.
Ethics. The study was performed according to the declaration of Helsinki and approved by the local ethical committee in Linköping, Sweden (M157-05). Median values were compared using Mann Whitney U-test for continuous data, and Chisquare test for comparison of proportions. Patient survival plots were calculated according to Kaplan-Meier, and log-rank test was used to examine differences between groups. Statistica v 13 was used for statistical work.
Results
Clinical characteristics of patients with GI disease in GPA and MPA. GI disease was diagnosed in 14 patients during the period 1987-2015, representing 6.5 % of all consecutive subjects in the registry (6.7% if tertiary patients and patients diagnosed before 1997 were excluded). Table 1 shows the general characteristics of patients with GI compared to those without GI disease, and Table 2 shows more clinical details about each of the 14 subjects with GI disease. The patients with GI disease were followed for a median follow up time of 6.8 (quartiles 3.2-15.2) years, and patients without GI disease for 7.5 (3.3-14.5) years.
Age, gender, GPA vs MPA, PR3-ANCA vs. MPO-ANCA, organ involvement, plasma creatinine, and CRP levels did not differ between the groups. However, disease activity assessed with BVAS at diagnosis was higher in patients with GI symptoms (p=0.001), and 11/14 patients with GI disease had renal involvement manifested by hematuria (and often albuminuria) but plasma creatinine levels was not increased in all cases.
As shown in Table 3 , GI symptoms were never the first symptom of GPA or MPA, GI symptoms and other GPA or MPA symptoms started concomitantly in only one patient, and only 6 patients had GI symptoms at the time of diagnosis of GPA or MPA. The median duration of GI symptoms was 28 days (range 1-102) ( Table 3) . Table 4 shows GI symptoms, as well as results of radiologic, endoscopic, and histologic examinations. Abdominal pain was the most common symptom, followed by nausea and bleeding. As shown in table 4 and 5, no patient had upper GI bleeding, whereas 7 of 14 patients had rectal bleeding (and further one case had an intraabdominal bleeding). However, bleeding was the main reason for more intensive care in only 5 cases (Table 5 ). Three out of seven patients with bleeding did not report abdominal pain. In patients with GI bleeding the severity differed between cases. Anemia was seen in all patients, and Table 5 shows the number of blood units given (2, 7, 9, 12, 12 units of blood transfusion and one case where data could not be extracted from the patient record). Three patients (No 6, 12, 13) experienced acute drop in blood pressure together with rapidly decreasing blood hemoglobin indicative of more extensive bleeding.
Radiologic findings. Radiology proved to be of great importance to indicate GI disease in GPA and MPA (Table 4) . During the period of 1987-1997, plain abdominal X-ray (first line examination in 4 patients without contrast and in 2 patients with oral/rectal contrast) was the standard radiologic method. With this method pneumoperitoneum can be identified, and by the use of oral contrast medium increased wall thickness could be visualized. In the later part of the study period computed tomography (CT) was utilized in most cases (first line examination in 7 patients and after plain X-ray in further 2 patients), and in addition to pneumoperitoneum and increased wall thickness CT also detected abscesses, hematoma, and ascites (Table 4) . Ultrasonography (US) (primarily in 2 patients) and magnetic resonance imaging (MRI) (1 patient) were less commonly used in this case series. US showed swollen intestinal walls in one patient, and in another subject an abscess was diagnosed and treated by US guided drainage. MRI detected wall thickening of the ileum in one patient. Bleeding scintigraphy was performed in one patient but was not conclusive. Table 4 , gastroscopy showed red and swollen esophageal, gastric, or duodenal mucosa indicative of inflammation in 3 of 5 patients. None of patients had ulcers. Vasculitis was confirmed by histology in 2 of these 3 patients with macroscopic signs (esophagus and duodenum, respectively). GI symptoms presented 71 days after diagnosis of MPA and at that time the weight had decreased 10 kg since diagnosis and CRP was 142 mg/L.
Endoscopy and histology findings. As shown in
One patient was treated with arterial coiling due to bleeding into the abdominal cavity (No 6).
Conservative therapy was sufficient in 6 patients with GI disease. This included bowel rest, antimicrobial therapy, parenteral nutrition, and blood transfusions in those with GI bleeding.
Immunosuppressive therapy, consisting of various combinations of high dose prednisolone, intravenous pulses of methylprednisolone, rituximab, cyclophosphamide, and plasma exchange, was continued, restarted or increased when GI involvement was diagnosed (Table   3) .
Patient survival and outcome. During the 1990:s two patients died because of GI disease 24 and 30 days after presentation of GI symptoms (Patient No 2 and 3). Further 3 patients died
10 months to 13 years after GI disease, but without relation to GPA or MPA. As shown in Figure 1 , patient survival assessed with Kaplan-Meier analysis did not reveal any differences comparing GPA or MPA patients with or without GI disease (p=0.89, log-rank test). No patient suffered from short bowel syndrome postoperatively.
Discussion
In this single center study of consecutive patients with GPA or MPA we found GI disease in 6% out of 216 patients. Previously most patients have been reported as case reports or small case series. Out of 45 subjects with GPA, Haworth reported four patients with GI disease in 1984 (7), and Pagnoux reported 6 GPA and 4 MPA from a register of 344 mixed vasculitides also including polyarteritis nodosa and eosinophil granulomatosis with polyangiitis (19) .
Contrary to this, GI manifestations were not mentioned in a case series of 158 GPA patients from 1998 (23), whereas Walton as early as 1958 found GI vasculitis in 22% of 56 autopsy cases with GPA (24) . When discussing frequency, selection bias is important to consider. For example, the patients in Walton´s series were all dead and probably represented cases with severe GPA. Since 1997 we treat and monitor all patients with GPA and MPA in our capture area, and the frequency of GI disease among the tertiary referred patients did not differ, so we believe 6 % is a representative figure for unselected patients with GPA and MPA. This figure is very similar to the 7% GI disease found in 673 subjects with MPA or GPA included in EUVAS or French clinical trials probably excluding less severe disease like patients with isolated ENT involvement (17) . The diagnosis of GI disease in GPA and MPA is not always straight forward. Therefore it is important to define GI disease in these patients in a standardized manner. We adopted the definitions proposed by Pagnoux in 2005. The symptoms should not be explained by GI infections (25, 26) , or simply be nausea caused by cyclophosphamide. In patients with left-sided colon perforation it can be difficult to distinguish between diverticulitis precipitated by vasculitis or as a complication to immunosuppressive therapy in a locus minoris, or a combination of both. Therefore, such cases were included in our study. Others have considered the GI manifestations in GPA and MPA as probably associated with the disease process rather than related to the use of immunosuppressive agents (4).
The most common symptoms were abdominal pain and rectal bleeding occurring in 79% and 50%, respectively. Similar rates have been reported by others (pain/bleeding in 97% in ref 19) . Diarrhea occurred in some of our patients and has also been reported previously (4) .
ANCA is associated with vasculitis preferentially in small and medium-sized vessels and usually not detectable with angiographic techniques. However, one patient with intraabdominal bleeding had angiographic micro-aneurysms in the inferior mesenteric artery which is consistent with vasculitis. GPA and MPA affecting also larger vessels have been described by others (27) (28) (29) (30) (31) (32) .
All patients had GPA or MPA symptoms from other organs, for example 11 of 14 patients had concomitant renal vasculitis manifested by urine abnormalities (hematuria and often albuminuria), but not always by increased plasma creatinine levels. The GI symptoms presented after the onset of other GPA or MPA symptoms in all but one patient, and after diagnosis of GPA or MPA in 8/14 patients. Thus, being aware of the patient's medical history and symptoms outside the gut are key issues for a surgeon confronted with a patient with GI symptoms, in order to make a timely diagnosis of GI involvement.
The diagnosis of GI disease relies on a combination of associated clinical symptoms and biopsies from other organs, and on ANCA analyses, as well as on imaging and endoscopy with biopsies from the GI tract. Abdominal CT was helpful in suggesting GI disease in many patients, but it cannot provide definite evidence. CT may show diffuse or multifocal bowel wall thickening with or without bowel distension or an abnormal enhancement pattern of the intestinal wall, but it may also be normal. Ascites and signs of perforation may also be seen (10) .
The role of endoscopy in the diagnosis of GI disease related to GPA or MPA is controversial (19) . It is common with normal macroscopic findings even in cases with severe involvement, and endoscopic biopsies are often inconclusive. However, uncharacteristic ulcers or an inflammatory picture may be found not only in the gastroduodenal and colonic tracts but also in the esophagus. The most typical endoscopic picture has been described as multiple, small, round and clear ulcers associated with obstructed blood flow (3). Furthermore, endoscopy can be of differential diagnostic importance. In this study, gastroscopy detected unspecific signs of inflammation in three of five patients, and colonoscopy showed unspecific macroscopic findings in one patient. Double balloon enteroscopy has been recommended as GI disease is often localized in the small bowel (3, 33) , and in one of our patients capsule endoscopy of the GI tract showed a swollen jejunal mucosa and focal inflammation of the duodenal bulb.
GI involvement was confirmed in specimens taken endoscopically or during surgery in some but far from all of our patients. In one report of GI involvement associated with different vasculitides, vasculitis could only be detected histologically in 3 of 36 biopsies during endoscopy, whereas surgical removed specimens showed signs of ischemic and/or thrombotic necrosis due to vasculitis in 8 of 9 cases (19) . In our study the diagnostic yield from endoscopic biopsies was somewhat better, while the yield from surgically removed specimens was 2 in 4. Supplementary Table summarizes GI findings in patients with GPA or MPA reported previously.
Due to corticosteroids and often frail patients in a bad general condition, the healing process is often hampered. This must be considered when surgery is necessary. One question is if primary anastomosis or temporary enterostomy should be performed in cases with intestinal perforation. Two of our patients with intestinal perforation went through successful resection and primary anastomosis of the intestine. These patients were previously healthy and had only received small amounts of immunosuppressive therapy preoperatively. In our other cases with GI perforation, intestinal resection was followed by creation of a temporary stoma, which may be a safer procedure especially if widespread inflammation or abscesses are present.
However, one of our patients did well after US-guided drainage and antibiotics of an abscess surrounding sigmoid diverticulitis.
If optimal immunosuppressive therapy is used the GI wall may heal after a couple of weeks.
However, during this period the GI wall is injured and surgery must therefore be considered in cases with perforation or continuing severe GI bleeding. In this study medical treatment alone was sufficient in nearly half of the patients. Eager surveillance with repeated CT scans is recommended as patients with high doses of corticosteroids may develop peritonitis without clinical signs.
Two of our 14 patients died because of the GI disease. However, compared to patients with GPA or MPA without GI disease, the patient survival was similar contrasting to previous studies where patients with GI disease had a worse prognosis (17, 20) . Although our case series reporting GI disease among patients with GPA or MPA is larger than many other series, the power to detect a real difference of survival is too limited. However, the survival curves are almost identical (Figure 1) , and one may speculate that an alternative explanation might be that the good outcome observed in this study has not occurred by chance, possibly due to early diagnosis and treatment, as well as more efficient and less toxic therapy during recent years. We also believe that a close co-operation between surgeons and rheumatologists is of benefit for the patient. Further studies are needed to answer if patient survival is as bad as previously thought and if survival has become better during recent years.
There is a general lack of evidence for how GI disease in GPA or MPA should be treated, and most recommendations are based on expert opinion. For example rituximab was in a recent European consensus document graded as equally effective as cyclophosphamide (34) , but there are only a few case reports concerning the use of rituximab in patients with MPA or GPA and GI involvement (35) .
In conclusion, we found that GI disease was a rare but significant complication in this large population based series of patients with GPA and MPA. 
